← Back to Analyst Consensus 
RNA Buy
Atrium Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | Roth Capital | initiate | — → Buy | — | 53% |
| Aug 14, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 6, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Jun 18, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| May 15, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Mar 11, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
Price Target Trend
Jul 8, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days